1
|
El K, Gray SM, Capozzi ME, Knuth ER, Jin E, Svendsen B, Clifford A, Brown JL, Encisco SE, Chazotte BM, Sloop KW, Nunez DJ, Merrins MJ, D'Alessio DA, Campbell JE. GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells. Sci Adv 2021; 7:7/11/eabf1948. [PMID: 33712466 PMCID: PMC7954443 DOI: 10.1126/sciadv.abf1948] [Citation(s) in RCA: 53] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Accepted: 01/26/2021] [Indexed: 05/23/2023]
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) communicates nutrient intake from the gut to islets, enabling optimal levels of insulin secretion via the GIP receptor (GIPR) on β cells. The GIPR is also expressed in α cells, and GIP stimulates glucagon secretion; however, the role of this action in the postprandial state is unknown. Here, we demonstrate that GIP potentiates amino acid-stimulated glucagon secretion, documenting a similar nutrient-dependent action to that described in β cells. Moreover, we demonstrate that GIP activity in α cells contributes to insulin secretion by invoking paracrine α to β cell communication. Last, specific loss of GIPR activity in α cells prevents glucagon secretion in response to a meal stimulus, limiting insulin secretion and driving glucose intolerance. Together, these data uncover an important axis by which GIPR activity in α cells is necessary to coordinate the optimal level of both glucagon and insulin secretion to maintain postprandial homeostasis.
Collapse
Affiliation(s)
- K El
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - S M Gray
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - M E Capozzi
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - E R Knuth
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - E Jin
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - B Svendsen
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - A Clifford
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - J L Brown
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - S E Encisco
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - B M Chazotte
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - K W Sloop
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - D J Nunez
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - M J Merrins
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - D A D'Alessio
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
- Division of Endocrinology, Department of Medicine, Duke University, Durham, NC, USA
| | - J E Campbell
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.
- Division of Endocrinology, Department of Medicine, Duke University, Durham, NC, USA
- Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA
| |
Collapse
|
2
|
Gilroy CA, Capozzi ME, Varanko AK, Tong J, D'Alessio DA, Campbell JE, Chilkoti A. Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia. Sci Adv 2020; 6:eaaz9890. [PMID: 32923621 PMCID: PMC7449677 DOI: 10.1126/sciadv.aaz9890] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 07/08/2020] [Indexed: 05/02/2023]
Abstract
There is great interest in identifying a glucagon-like peptide-1 (GLP-1)-based combination therapy that will more effectively promote weight loss in patients with type 2 diabetes. Fibroblast growth factor 21 (FGF21) is a compelling yet previously unexplored drug candidate to combine with GLP-1 due to its thermogenic and insulin-sensitizing effects. Here, we describe the development of a biologic that fuses GLP-1 to FGF21 with an elastin-like polypeptide linker that acts as a sustained release module with zero-order drug release. We show that once-weekly dual-agonist treatment of diabetic mice results in potent weight-reducing effects and enhanced glycemic control that are not observed with either agonist alone. Furthermore, the dual-agonist formulation has superior efficacy compared to a GLP-1/FGF21 mixture, demonstrating the utility of combining two structurally distinct peptides into one multifunctional molecule. We anticipate that these results will spur further investigation into GLP-1/FGF21 multiagonism for the treatment of metabolic disease.
Collapse
Affiliation(s)
- C. A. Gilroy
- Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA
- Department of Nutritional Sciences and Toxicology, University of California, Berkeley, CA 94720, USA
| | - M. E. Capozzi
- Duke Molecular Physiology Institute, Duke University, Durham, NC 27701, USA
| | - A. K. Varanko
- Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA
| | - J. Tong
- Duke Molecular Physiology Institute, Duke University, Durham, NC 27701, USA
- Department of Medicine, Duke University, Durham, NC 27701, USA
| | - D. A. D'Alessio
- Duke Molecular Physiology Institute, Duke University, Durham, NC 27701, USA
- Department of Medicine, Duke University, Durham, NC 27701, USA
| | - J. E. Campbell
- Duke Molecular Physiology Institute, Duke University, Durham, NC 27701, USA
- Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27701, USA
| | - A. Chilkoti
- Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA
| |
Collapse
|
3
|
Palmer GM, Tiran Z, Zhou Z, Capozzi ME, Park W, Coletta C, Pyriochou A, Kliger Y, Levy O, Borukhov I, Dewhirst MW, Rotman G, Penn JS, Papapetropoulos A. A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. Br J Pharmacol 2012; 165:1891-1903. [PMID: 21943108 DOI: 10.1111/j.1476-5381.2011.01677.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND AND PURPOSE Pathological angiogenesis is associated with various human diseases, such as cancer, autoimmune diseases and retinopathy. The angiopoietin (Ang)-Tie2 system plays critical roles in several steps of angiogenic remodelling. Here, we have investigated the anti-angiogenic effect of a novel angiopoietin-derived peptide. EXPERIMENTAL APPROACH Using computational methods, we identified peptides from helical segments within angiopoietins, which were predicted to inhibit their activity. These peptides were tested using biochemical methods and models of angiogenesis. The peptide with best efficacy, A11, was selected for further characterization as an anti-angiogenic compound. KEY RESULTS The potent anti-angiogenic activity of A11 was demonstrated in a multicellular assay of angiogenesis and in the chorioallantoic membrane model. A11 bound to angiopoietins and reduced the binding of Ang-2 to Tie2. A11 was also significantly reduced vascular density in a model of tumour-induced angiogenesis. Its ability to inhibit Ang-2 but not Ang-1-induced endothelial cell migration, and to down-regulate Tie2 levels in tumour microvessels, suggests that A11 targets the Ang-Tie2 pathway. In a rat model of oxygen-induced retinopathy, A11 strongly inhibited retinal angiogenesis. Moreover, combination of A11 with an anti-VEGF antibody showed a trend for further inhibition of angiogenesis, suggesting an additive effect. CONCLUSIONS AND IMPLICATIONS Our results indicate that A11 is a potent anti-angiogenic compound, through modulation of the Ang-Tie2 system, underlining its potential as a therapeutic agent for the treatment of ocular and tumour neovascularization, as well as other pathological conditions that are dependent on angiogenesis.
Collapse
Affiliation(s)
- G M Palmer
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Z Tiran
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Z Zhou
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - M E Capozzi
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - W Park
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - C Coletta
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - A Pyriochou
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Y Kliger
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - O Levy
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - I Borukhov
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - M W Dewhirst
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - G Rotman
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - J S Penn
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - A Papapetropoulos
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USACompugen Ltd, Tel-Aviv, IsraelLaboratory for Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, GreeceDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA
| |
Collapse
|